aim study evaluate effect oral prevention chronic obstructive pulmonary disease copd exacerbations using pharmacomorbidity linkage pharmo authors included patients aged NUMBER yrs dispensed medication labelled respiratory indications anatomical therapeutic chemical atc classification r03 hospitalised copd international classification diseases NUMBER NUMBER NUMBER time frame subjects subsequently divided groups received following discharge admission patients studied starting initial discharge readmission death end data collection period maximum period NUMBER yr total NUMBER patients hospitalised copd included study adjustment disease severity observed use significantly associated reduced risk readmission readmission risk significantly lower patients high average daily doses conclusion observed reduces risk rehospitalisation chronic obstructive pulmonary disease approximately NUMBER risk reduction n acetylcysteine hospitalisation NUMBER NUMBER icd NUMBER n acetylcysteine NUMBER NUMBER follow NUMBER NUMBER n acetylcysteine n acetylcysteine n acetylcysteine dose dependent